Exact Sciences's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Exact Sciences's ROA in the fourth quarter of 2025?
Exact Sciences Corporation recorded a cumulative net loss of $-208 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on assets (ROA) of -3.57%.

However, within the Healthcare sector 282 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Dec 31 2025 quarter, so far to 3345, from total ROA ranking in the third quarter of 2025 at 3478.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Total Assets Change	-1.14 %	-12.57 %	-13.13 %	-10.43 %	-8.39 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-208	-987	-1,005	-1,020	-1,029
Return On Assets (TTM)	-3.57 %	-16.91 %	-16.63 %	-16.28 %	-16 %
EXAS's Total Ranking	# 3345	# 3478	# 3492	# 3529	# 4080
Total Assets (TTM) in million	5,861	5,900	5,797	5,711	5,928
Seq. Total Assets Change	-0.67 %	1.77 %	1.51 %	-3.66 %	-12.16 %
Seq. Net Income Change	-	-	-	-	-

EXAS's 5 Years Annual ROA >> Back to EXAS Management Effectiveness >> Compare EXAS ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 18
Sector	# 283
Overall	# 3317

Return On Assets Statistics
High	Average	Low
-2.7 %	-23.85 %	-52.47 %
(Jun 30 2024)		(Dec 31 2012)

Financial Statements
Exact Sciences's Assets	$ 5,861 million	EXAS's Balance sheet
Exact Sciences's Income	$ -86 million	Quarterly EXAS's Income Statement
EXAS's Income by Division		See EXAS's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2021	(Dec 31 2020) FY 2020
Y / Y Total Assets Change	-1.14 %	-8.39 %	3.93 %	26.43 %	40.49 %
Total Assets in million	5,861	5,928	6,471	6,227	4,925
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-208	-1,029	-204	-624	-849
Annual Return On Assets	-3.55 %	-17.36 %	-3.15 %	-10.01 %	-17.23 %

EXAS's 5 Years Annual ROA >> Back to EXAS Management Effectiveness >> Compare EXAS ROA to its Competitors

More Return On Assets Ratios
EXAS's' Return on Assets at Yahoo Finance
Medical Laboratories Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
EXAS's Roa Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for EXAS's Competitors
Subscribers only: Roa for Exact Sciences's Suppliers
Subscribers only: Return On Assets for EXAS's Customers

You may also want to know
EXAS's Roi	EXAS's Inventory Turnover Ratio	EXAS's Growth Rates	EXAS's Dividend Comparisons
	EXAS's Profitability Ratios	EXAS's Asset Turnover Ratio	EXAS's Dividend Growth
EXAS's Roe	EXAS's Valuation Ratios	EXAS's Financial Strength Ratios	EXAS's Dividend Payout Ratio

Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector

ROA

Date modified: 2026-06-22T16:30:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.